Sermorelin for Testosterone: What the Evidence Shows
What human and animal studies show about Sermorelin for testosterone, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Human observational
- Human studies
- 2
- PubMed records, our ledger
- Animal studies
- 0
- PubMed records, our ledger
- Studies we summarised
- 1
- with an outcome for testosterone
Evidence for testosterone
Each row is an outcome related to testosterone from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Serum IGF-1 | Mean IGF-1 rose from 159.5 ng/mL at baseline to 239.0 ng/mL after combined GHRP/sermorelin therapy (retrospective, multi-peptide combination, no control). | Human observationaln = 14 | American journal of men's health 2017, PMID 28830317 |
PubMed records for Sermorelin and testosterone: 2 human, 0 animal (search counts, not studies we reviewed). Grades follow our evidence scale.
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
Other peptides people research for testosterone
All peptides for testosterone, comparedCommon questions
Does Sermorelin help with testosterone?
The strongest study we summarise for testosterone is human observational evidence, across 1 study with an outcome for testosterone. That is not proof it works in people.
Is Sermorelin approved for testosterone?
No. Sermorelin is not FDA approved for any use, including testosterone.
What is the best peptide for testosterone?
There is no single answer. Our testosterone overview compares each candidate by evidence grade and legal status rather than by popularity.
More on Sermorelin
Sources
- 1Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.American journal of men's health · 2017PMID 28830317Accessed 2 Oct 2026
Found an error? Report a correction.